For Immediate Release: Thursday, March 21, 2024, 1:30 pm U.S. Eastern Time Media Contact: Kara Flynn, 202.257.8424, press@ashg.org ROCKVILLE, MD - The American Society of Human Genetics (ASHG) thanks Congress for sustaining its support for biomedical research in the FY 2024 conference agreement by funding the National Institutes of Health (NIH) at $47.1 billion. In a... Read More
Posted By: HGG Advances HGGA: What motivated you to start working on this project? GP: Non-alcoholic fatty liver disease is a silent epidemic, and 25% of Americans are affected by it. There are currently not any medications approved for this disease. This is partly because we poorly understand the genetic mechanisms associated with this disease.... Read More
Posted By: Kylee Spencer, PhD, Assistant Editor, AJHG KS: What motivated you to start working on this project? HW: We know from eQTL studies that trans-acting loci tend to have smaller effect sizes than cis-acting loci. By aggregating cis-acting effects into one predicted expression level, as is done in the TWAS method PrediXcan, we had... Read More
For Immediate Release: Thursday, February 15, 2024, 3:00pm U.S. Eastern Time Media Contact: Kara Flynn, 202.257.8424, press@ashg.org ROCKVILLE, MD - The American Society of Human Genetics (ASHG) is excited to announce the selection of Amanda Perl as the organization’s next Chief Executive Officer. Perl has served in numerous association leadership positions with deep experience in strategic... Read More
Posted By: Kylee Spencer, PhD, Assistant Editor, AJHG KS: What motivated you to start working on this project? SG: Tumor Mutational Burden (TMB) is one of a few FDA approved biomarkers for immunotherapy in solid tumors but the mechanisms for why certain tumors are TMB-high and why certain TMB-high tumors still do not respond to... Read More